proportional hazards

Related by string. * Proportional : proportional spacing . proportional representation PR . equally proportional . proportional representation . directly proportional . inversely proportional . Proportional Representation PR / Hazards . hazarded . hazarding . HAZARDS : pose choking hazards . tripping hazards . choking hazards . THE INHERENT HAZARDS OF . geologic hazards . strangulation hazards * *

Related by context. All words. (Click for frequent words.) 73 regression analyzes 73 univariate 70 multivariate Cox 70 Kaplan Meier method 70 multivariable logistic regression 69 Kaplan Meier survival 68 multivariate logistic regression 68 multivariate analyzes 68 regression analysis 68 multivariable Cox 67 Univariate 66 Logistic regression 66 Kaplan Meier analysis 65 conditional logistic regression 65 Poisson regression 65 covariates 65 covariate 65 logistic regression 65 logistic regression models 64 multiple logistic regression 64 logistic regression analysis 64 Multivariate logistic regression 64 Linear regression 64 Kaplan Meier 63 Multivariable 63 nonparametric 63 multiple linear regression 63 bivariate 63 univariate analysis 62 multivariate regression 62 multivariable analysis 62 Mantel Haenszel 62 confidence intervals CIs 62 univariate analyzes 62 Multiple logistic regression 62 odds ratios ORs 62 Multivariate 62 multivariable 62 multivariate regression analysis 61 multivariable adjusted 61 multivariate analysis 61 logistic regression model 60 chi squared 60 Subgroup analyzes 60 Multivariate analysis 60 HER2 expression 59 generalized linear 59 HOMA IR 59 Descriptive statistics 59 nomogram 59 binary logistic regression 59 explanatory variables 59 Kaplan Meier curves 58 stepwise logistic regression 58 Kruskal Wallis test 58 linear regression analysis 58 clinicopathological 58 rs# [004] 58 Logistic regression analysis 58 multivariable regression 58 ANOVA 58 covariance 58 PSADT 58 intraobserver 57 symptomatic VTE 57 Univariate analysis 57 interobserver reliability 57 recursive partitioning 57 Multiple linear regression 57 generalized estimating 57 colorectal adenoma 57 biochemical recurrence 57 VKORC1 57 hormone receptor status 56 ABCB1 56 prognostic factors 56 Child Behavior Checklist 56 meta regression 56 RRM1 56 clinico pathological 56 glomerular filtration rate 56 Pharmacokinetic parameters 56 APOC3 56 variant rs# 56 allele frequencies 56 preoperative PSA 56 potential confounders 56 logistic regression analyzes 56 serum estradiol 56 intima media thickness 56 Multivariable logistic regression 56 F FDG PET 55 morphometric vertebral fractures 55 meta analytic 55 interobserver 55 histologic subtype 55 prostate cancer CaP 55 pharmacokinetics PK 55 exhaled nitric oxide 55 APOE genotype 55 linear regression 55 NMIBC 55 immunohistochemical staining 55 genotypic resistance 55 variance ANOVA 55 cystatin C 55 convergent validity 55 etiologic 55 multivariate 55 adenoma recurrence 55 electrophysiologic 55 MDRD 55 prognostic variables 55 logistic regressions 55 Bonferroni 55 multivariate adjusted 55 CYP#D# genotype 55 logit 55 Kaplan Meier estimates 55 Subgroup analysis 55 Secondary efficacy endpoints 55 creatinine clearance 55 mL/min/#.# m 2 55 sensitivity specificity 55 HER2 overexpression 54 SNP rs# [002] 54 coronary stenosis 54 hierarchical clustering 54 QTcF 54 spirometric 54 predictor variables 54 prostate cancer PCa 54 K ras mutations 54 Insulin sensitivity 54 mammographic density 54 ARB telmisartan 54 carotid IMT 54 lumbar spine BMD 54 pairwise comparisons 54 DAS# scores 54 tumor histology 54 Pearson correlation coefficients 54 endometrial thickness 54 histological subtype 54 Comorbidity 54 MDRD equation 54 unpaired t 54 System IPSS 54 MTHFR 54 GnRH agonist 54 sociodemographic factors 54 albumin creatinine ratio 54 bivariate analysis 54 estimated GFR 54 QTc prolongation 54 cytologic 54 genetic polymorphisms 54 AST ALT 54 immunohistochemical 54 estimated glomerular filtration 54 urothelial carcinoma 54 posttreatment 54 pCR 54 intact parathyroid hormone 54 prognostic significance 54 Cardiorespiratory fitness 54 tertiles 54 residual confounding 54 serum GGT 54 NHANES III 54 gene polymorphisms 54 aminotransferase levels 54 virologic responses 53 categorical variables 53 androgen suppression 53 retrospective cohort 53 familial aggregation 53 Framingham Offspring 53 SCr 53 xenograft models 53 linear regression analyzes 53 highest tertile 53 Kruskal Wallis 53 differential gene expression 53 confidence interval CI 53 mycophenolate mofetil 53 nodal metastasis 53 Interrater reliability 53 ROC curves 53 Sensitivity specificity 53 confounders 53 idraparinux 53 multivariate adjustment 53 Bonferroni correction 53 CVD mortality 53 μmol L 53 Cystatin C 53 Primary endpoints 53 multivariable analyzes 53 airway hyperresponsiveness 53 morphometric 53 galiximab 53 rs# [002] 53 postmenopausal hormone 53 hsCRP levels 53 recurrent venous thromboembolism 53 apolipoproteins 53 ANCOVA 53 Kaplan Meier curve 53 HAQ DI 53 -#.# log# copies mL 53 Tasigna prolongs 53 EQ 5D 53 WOMAC pain 53 TT genotype 53 metabolic parameters 53 QTc 53 relapsed MM 53 nonfatal MI 53 HNSCC 53 progression TTP 53 Wilcoxon rank sum 53 P = .# 53 Secondary endpoints include 53 inhibin B 53 composite endpoint 53 Observational studies 53 invasive lobular 53 APOE e4 53 echocardiographic parameters 53 prognostic biomarker 53 MMSE score 53 transabdominal 53 MLH1 53 intraclass correlation coefficients 53 affective psychosis 53 predictive validity 53 CYP#D# gene 53 confidence interval #.#-#.# 53 prospectively defined 53 CHD mortality 52 albumin excretion rate 52 Hidden Markov 52 CYP#C# [001] 52 CR nPR 52 fulvestrant 52 PSA kinetics 52 HER2 amplification 52 advanced adenoma 52 FDG PET imaging 52 bronchopulmonary dysplasia BPD 52 % CI #.#-#.# [006] 52 tamoxifen Nolvadex ® 52 covariance ANCOVA 52 aldosterone antagonist 52 transient elastography 52 mRS 52 mRNA expression 52 BRCA2 mutation carriers 52 pharmacodynamic parameters 52 NIHSS score 52 subgroup analyzes 52 Index CDAI 52 % Confidence Interval 52 SUVmax 52 Meta analyzes 52 YMRS 52 PSA nadir 52 SSc 52 genomewide 52 Reynolds Risk Score 52 rs# [001] 52 glycated hemoglobin levels 52 Glomerular filtration rate 52 prognostic indicators 52 femoral neck BMD 52 lowest tertile 52 leukocyte counts 52 subclinical atherosclerosis 52 neurologic progression 52 myocardial viability 52 recurrent glioblastoma multiforme 52 #.#ng/ml 52 Histologic 52 nondiabetic patients 52 neurodevelopmental impairment 52 octreotide LAR 52 clinicopathological features 52 Multivariate analyzes 52 NIHSS 52 KRAS mutation status 52 symptomatic intracerebral hemorrhage 52 pharmacodynamic PD 52 adjuvant systemic 52 transcranial Doppler ultrasound 52 tHcy 52 HRCT 52 aminotransferases 52 serum creatinine levels 52 irbesartan 52 intima media thickness IMT 52 histologic 52 confounding variables 52 pharmacodynamic effects 52 serum PSA 52 semiquantitative 52 plasma cortisol 52 serum retinol 52 nomograms 52 Mendelian randomization 52 Lp PLA 2 52 GAMMAGARD 52 ziprasidone 52 KRAS mutations 52 serum calcium 52 urodynamic 52 noninferiority 52 rosuvastatin #mg 52 lactate dehydrogenase LDH 52 endometrial carcinoma 52 neurocognitive function 52 serum leptin 52 methacholine challenge 52 chemoradiotherapy 52 microsatellite instability 52 noncarriers 52 airway responsiveness 52 nonvertebral fractures 52 plasma leptin 52 vincristine doxorubicin 52 ASCUS 52 node metastases 52 glycosylated hemoglobin HbA1c 52 histologically confirmed 52 postintervention 52 bivariate analyzes 52 RECIST Response Evaluation Criteria 52 lymph node metastasis 52 pg ml 52 ADCS CGIC 52 Lp PLA2 51 Histopathologic 51 warfarin dosage 51 nonmetastatic 51 hormone receptor negative 51 leukocyte count 51 Hazard Ratio 51 normotensive 51 distant metastasis 51 correlation coefficients 51 tumor progression TTP 51 Hamilton Anxiety Scale 51 nonrandomized 51 fasting insulin 51 inferential statistics 51 kidney allograft 51 pharmacodynamic markers 51 proband 51 achieved statistical significance 51 parous women 51 antidiabetic medication 51 extrapyramidal symptoms 51 genotypic 51 metabolite concentrations 51 MTT assay 51 Secondary endpoints included 51 paricalcitol 51 AUC0 51 clinically localized prostate 51 mean ± SEM 51 corrected QT interval 51 Angiotensin converting enzyme 51 CrCl 51 biochemical relapse 51 progesterone receptor PR 51 Ki# 51 tertile 51 androgen deprivation 51 prospectively randomized 51 lipid abnormalities 51 rheumatoid factor 51 sociodemographic characteristics 51 conventional DMARDs 51 Secondary endpoints 51 ERCC1 51 viral kinetics 51 definite stent thrombosis 51 TIMP 1 51 lymphocyte count 51 radiographic progression 51 statistically nonsignificant 51 = #.#-#.# 51 unmeasured confounders 51 plus octreotide LAR 51 chromosomal aberrations 51 HIV RNA 51 neoadjuvant chemotherapy 51 Efficacy endpoints 51 inflammatory biomarkers 51 antiretroviral naïve 51 Regression analysis 51 #q# deletion syndrome 51 waist circumference WC 51 serum concentrations 51 log# copies mL 51 Baseline characteristics 51 FDG PET 51 virologic failure 51 Doppler echocardiography 51 serum cortisol 51 serum urate 51 SHBG levels 51 IPAH 51 hematological parameters 51 mineral density BMD 51 cerebral microbleeds 51 estrogen receptor ER 51 prostate carcinoma 51 Symptom severity 51 creatinine ratio 51 Regression analyzes 51 prospective observational studies 51 nonfasting triglyceride levels 51 poor metabolizers 51 left ventricular diastolic 51 Carotid Revascularization Endarterectomy vs. 51 inhospital mortality 51 prognostic indicator 51 methotrexate monotherapy 51 hip resurfacing arthroplasty 51 clinicopathologic 51 psychiatric comorbidity 51 RRs 51 histopathologic 51 Pharmacodynamic 51 confounder 51 locoregional recurrence 51 ExTRACT TIMI 51 immunoreactivity 51 lung metastasis 51 CYP#D# inhibitor 51 attain statistical significance 51 plasma folate 51 atazanavir ritonavir 51 Hb A1C 51 #q# deletion 51 transvaginal sonography 51 dose Iluvien 51 serum phosphorous 51 valvulopathy 51 PCWP 51 NSABP B 51 Crohn Disease Activity 51 EURIDIS 51 -#.# log# 51 hsCRP 51 LHRH receptor positive 51 histopathological 51 lipid lowering drugs 51 immunosuppressive regimen 51 Prognostic factors 51 International Prognostic Scoring 51 CIN2 + 51 Sensitivity analyzes 51 liver histology 51 haematologic 51 adenomatous 51 ROC curve 51 bone scintigraphy 51 â ‰ ¥ 51 BMI z 51 surrogate markers 51 gallstone disease 51 postoperative mortality 51 calculated creatinine clearance 51 EGFR HER2 51 cytogenetic abnormalities 51 abacavir lamivudine 51 intraventricular hemorrhage 51 UKPDS 51 DAS# CRP 51 BRCA2 carriers 51 Prognostic significance 51 transgene expression 51 allelic 50 serum phosphate 50 Visual Analogue Scale VAS 50 Tg mice 50 Supplementary Table 50 intraclass correlation coefficient 50 stage IIIb IV 50 IL#B 50 median PFS 50 deCODE BreastCancer TM 50 doxorubicin docetaxel 50 heterozygotes 50 eplerenone 50 lymphovascular invasion 50 serum triglycerides 50 atypical hyperplasia 50 microarray experiments 50 apparent diffusion coefficient 50 CTEPH 50 Pearson correlation coefficient 50 Depression Inventory 50 inhaled budesonide 50 serum biomarker 50 dose proportionality 50 ventilation perfusion 50 Cytogenetic 50 KRAS status 50 hematopoietic cancers 50 neutrophil counts 50 thyroid hormone levels 50 D dimer 50 glycosylated hemoglobin levels 50 platelet reactivity 50 periprocedural 50 immunohistochemical analysis 50 tumor subtype 50 GABRA2 50 incomplete revascularization 50 thromboembolism 50 PTPN# 50 lactate dehydrogenase 50 preoperative chemotherapy 50 HIV tropism 50 Unified Parkinson Disease 50 Rating Scale BPRS 50 apolipoprotein B 50 molecular subtypes 50 Randomized clinical trials 50 KIF6 carriers 50 tipranavir ritonavir 50 progesterone receptor negative 50 Pharmacokinetic 50 β blockers 50 sFlt 1 50 serum testosterone 50 hydroxyvitamin D levels 50 CaPSURE 50 dapagliflozin plus 50 % CI #.#-#.# [003] 50 genes CYP#C# 50 antibody titer 50 thyrotropin levels 50 latent celiac disease 50 PITX2 50 eNO 50 angiotensin converting enzyme inhibitors 50 nonresponders 50 serum IGF 50 glomerular filtration 50 ESR1 50 sulphonylureas 50 interrater reliability 50 GSTP1 50 pegylated interferon alfa 2b 50 ertapenem 50 virological response 50 ADAS cog 50 null hypothesis 50 serum PTH 50 comorbidity 50 FGFR2 gene 50 tumorigenicity 50 2 diabetes T2D 50 gene APOE 50 Genotypic 50 urine albumin 50 % CI #.#-#.# [007] 50 nondemented 50 methylenetetrahydrofolate reductase 50 atorvastatin #mg 50 hepatic fibrosis 50 ALT elevation 50 enzyme immunoassay EIA 50 FeNO 50 miRNA expression 50 SSRI citalopram 50 binomial model 50 longitudinal cohort study 50 Multicenter AIDS 50 LV dysfunction 50 surrogate endpoint 50 Y BOCS 50 HCV SPRINT 50 retinol binding protein 50 correlational 50 axial length 50 ADRB2 50 baseline HbA1c 50 urinary N telopeptide 50 breast carcinoma 50 statistical significance p 50 echocardiographic 50 preintervention 50 genotype phenotype 50 somatostatin analog 50 CD# expression [002] 50 death reinfarction 50 renal cortical 50 plasma pharmacokinetics 50 retest reliability 50 BEXXAR Therapeutic Regimen 50 observational cohort 50 dyssynchrony 50 psychosocial variables 50 bioprosthetic valve 50 differentially expressed genes 50 abnormal cytology 50 IV bisphosphonates 50 NAMCS 50 serum albumin 50 Duration Gap 50 left ventricular systolic 50 Swedish Mammography Cohort 50 neuropathological 50 Viral load 50 nonvertebral fracture 50 serum aminotransferase levels 50 locoregional 50 sociodemographic 50 MetS 50 mg kg dose 50 depressive symptom 50 creatinine clearance CrCl 50 Framingham Risk Score 50 Rating Scale UPDRS 50 prospective multicentre 50 mucinous 50 vaso occlusive crisis 50 pmol L 50 euthymic patients 50 beta blocker therapy 50 ALB # 50 ERBB2 50 liver biopsies 50 baseline serum creatinine 50 HbA 1c 50 epistasis 50 NSTE ACS 50 tibolone 50 LV ejection fraction 50 TRUS 50 fetuin 50 Histological 50 prospective cohort 50 carotid atherosclerosis 50 Cronbach 50 x ULN 50 caspofungin 50 BRCA1 mutations 50 Adjuvant chemotherapy 50 pulmonary exacerbations 50 quadratic 50 efavirenz EFV 50 colorectal neoplasia 50 peak VO2 50 dimensional echocardiography 50 placebo controlled clinical 49 prolonged QT interval 49 COMT genotype 49 LDH lactate dehydrogenase 49 ultrasonographic 49 APOL1 49 plasma adiponectin 49 QIDS SR 49 rFSH 49 Echocardiographic 49 transferrin saturation 49 unmeasured confounding 49 BPS IC 49 affective disorders 49 % CI #.#-#.# [001] 49 TEAEs 49 thymoma 49 NLSY 49 visceral adiposity 49 protein excretion 49 carotid artery intima media 49 primary aldosteronism 49 NNT = 49 6MWD 49 elevated ALT 49 microarray gene expression 49 subclinical hypothyroidism 49 tumor regressions 49 maternal serum 49 operable breast cancer 49 baseline LDH 49 ADHD Rating Scale 49 fundus photography 49 vertebral fracture 49 TNF blocker therapy 49 pg mL 49 hemoglobin A1c levels 49 histopathologic findings 49 IKDC 49 TAXUS Express Stent 49 adjuvant cisplatin 49 resected pancreatic cancer 49 retrospective cohort study 49 orofacial clefts 49 microalbumin 49 pretreatment serum 49 Prognostic 49 placebo fluoxetine 49 carotid artery thickness 49 IFN α 49 CC genotype 49 immunostaining 49 plasma triglycerides 49 binary restenosis 49 endometrial hyperplasia 49 carcinoembryonic antigen 49 nadroparin 49 exemestane 49 HbA1C levels 49 nicardipine 49 serum creatinine 49 DLTs 49 coinfected patients 49 PREZISTA r 49 advanced adenomas 49 BRAF V#E mutation 49 FDG uptake 49 angiographic outcomes 49 RASSF1A 49 MAGE A3 ASCI 49 APTIVUS r 49 Randomized trials 49 FDG PET scan 49 prostate carcinogenesis 49 obstructive coronary artery 49 serum biomarkers 49 elevated serum creatinine 49 insulin glargine 49 hippocampal volume 49 mcg QD 49 histopathologic diagnosis 49 GRNCM1 49 timepoints 49 pretransplant 49 #OHD 49 FDG PET scans 49 HbA 1c levels 49 neurodevelopmental outcome 49 bronchopulmonary dysplasia 49 MR spectroscopy 49 Hazard Ratio HR 49 neoadjuvant 49 desvenlafaxine succinate 49 corticosteroid dose 49 serum markers 49 Depressive symptoms 49 hamartoma 49 ADAS Cog 49 alanine aminotransferase 49 psychopathological symptoms 49 response pCR 49 radiotherapy RT 49 aspartate aminotransferase AST 49 differentiated thyroid 49 Suicidal ideation 49 eGFR 49 papillary renal cell carcinoma 49 prespecified 49 factorial design 49 FOLFIRI alone 49 esophageal carcinoma 49 statistically significant p = 49 RT PCR assay 49 fluvastatin 49 Inventory BPI 49 PCa 49 missense mutations 49 carotid plaque 49 transcriptional profiling 49 cerebral oxygenation 49 RECIST criteria 49 hip BMD 49 abstinent alcoholics 49 urinary albumin 49 laboratory abnormalities 49 regression coefficient 49 HyQ 49 Main Outcome Measures 49 epoetin beta 49 mutated K ras 49 susceptibility locus 49 lopinavir r 49 pT3 49 alanine aminotransferase ALT 49 MGUS 49 SNP rs# [001] 49 FDA defined valvulopathy 49 interrater 49 urinary albumin excretion 49 serum BDNF 49 hepatorenal syndrome 49 ratio WHR 49 T2D 49 TOP2A 49 Ceplene/IL-2 49 QT intervals 49 prognostic factor 49 pT 49 prespecified secondary 49 AUCs 49 hypercholesterolemia 49 nonpregnant women 49 subtrochanteric 49 Cardiopulmonary bypass 49 alexithymia 49 nonsignificant 49 -#.# mg dL [002] 49 nonsignificant difference 49 contrast echocardiography 49 microRNA expression 49 thickness IMT 49 HIV seroconversion 49 cyclophosphamide methotrexate 49 periprocedural MI 49 ezetimibe simvastatin 49 mg BID dose 49 demonstrated clinically meaningful 49 SELENA SLEDAI 49 p = #.# [002] 49 serum CRP 49 BODE index 49 Visual Analog 49 diuretic chlorthalidone 49 resectable pancreatic cancer 49 imatinib therapy 49 HLA DRB1 SE 49 % CI #.#-#.# [002] 49 airway remodeling 49 activated partial thromboplastin 49 Immunohistochemical analysis 49 posttest 49 serum HBV DNA 49 elevated transaminases 49 umbilical artery 49 advanced neoplasia 49 thyroglobulin 49 chlorthalidone 49 gastric cardia 49 glutamate glutamine 49 secretin 49 methylation patterns 49 FDG-PET/CT 49 susceptibility loci 49 PON1 49 Brief Psychiatric 49 drotrecogin alfa activated 49 prospectively evaluated 49 Papillary 49 transcranial Doppler 49 MELD scores 49 Lenalidomide 49 oxycodone CR 49 nonfasting triglycerides 49 fetal malformations 49 prednisone prednisolone plus 49 5-FU/LV 49 asymptomatic carotid stenosis 49 genetic variants associated 49 mild renal insufficiency 49 adiponectin concentrations 49 Mania Rating Scale 49 regression 49 BRCA1 mutation carriers 49 ER CHOP 49 rs# [003] 49 patients undergoing CABG 49 ng dL 49 hemodynamically significant 49 gene expression microarrays 49 clinically meaningful differences 49 gene polymorphism 49 SLN biopsy 49 fraternal twin pairs 49 elevated fasting glucose 49 serum homocysteine 49 albumin excretion 49 moderate renal impairment 49 premorbid 49 mineral density 49 shorter telomere length 49 serum cotinine 49 XIENCE V PROMUS Stent 49 pegylated IFN 49 DAS# remission 49 serum potassium 49 histologically proven 49 squamous histology 49 atherothrombotic disease 49 hemostatic efficacy 49 antithymocyte globulin 49 liver transplant recipients 49 Health Assessment Questionnaire 49 aMCI 49 serum HCV RNA 49 cardiac repolarization 49 χ 49 bioavailable testosterone 48 INTERHEART study 48 fluorodeoxyglucose positron emission tomography 48 p = .# [002] 48 SSRI SNRI 48 NYHA functional class 48 plus medroxyprogesterone acetate 48 impaired endothelial 48 PRIMO CABG2 48 TNM staging 48 lognormal 48 CI -#.# 48 QEEG 48 chemosensitivity 48 oral diclofenac 48 serum folate 48 placebo dexamethasone 48 polyp recurrence 48 tipranavir r 48 carotid intima media 48 Main Outcome Measure 48 anemia neutropenia 48 transthoracic 48 systolic BP 48 d dimer 48 Median progression 48 mITT population 48 stratifying patients 48 virologic response 48 pancreatic adenocarcinoma 48 HOXB# 48 rho = 48 lispro 48 pharmacokinetic PK 48 serum urate levels 48 HAM D# 48 microsimulation model 48 deCODE AF TM 48 monozygotic 48 antidiabetic medications 48 histone modifications 48 plasma lipid 48 NIH CPSI 48 anti JCV antibodies 48 complete cytogenetic response 48 NATRECOR ® 48 Stent thrombosis 48 -#.# ± [002] 48 plasma homocysteine 48 vitro experiments 48 Radiometric dating 48 demographic variables 48 orthologous genes 48 Neuropsychiatric Inventory NPI 48 placebo controlled dose escalation 48 oophorectomy 48 Cronbach alpha 48 prostatic adenocarcinoma 48 depressive symptomatology 48 ibandronate 48 promoter methylation 48 Skin sterol 48 Zevalin consolidation 48 autonomic dysfunction 48 hematologic toxicity 48 RE LY ® 48 GG genotype 48 carotid plaques 48 serum magnesium 48 Multivariate analysis revealed 48 cTnT levels 48 FEV ^ sub 48 troponins 48 ABC/3TC 48 telomere lengths 48 β blocker 48 RAPAFLO R 48 HCV RESPOND 2 48 murine models 48 EBRT 48 PCI ExTRACT TIMI 48 lignan intake 48 linear regressions 48 severe exacerbations 48 elevated CRP 48 karyotypes 48 Haptoglobin 48 bronchoalveolar lavage BAL 48 parous 48 ischemic cardiovascular 48 multivariate statistical 48 chromosome #p# [002] 48 apo B

Back to home page